Biotechnology
On April 23, 2026, the FDA granted accelerated approval to Regeneron's Otarmeni, the first gene therapy ever approved for genetic hearing loss—a breakthrough that represents a categorical shift in what medicine can do.
Biotechnology
Kyverna Therapeutics presented groundbreaking KYSA-8 trial data showing that a single CAR-T cell infusion could achieve what years of immunosuppression cannot: a durable immune reset in stiff person syndrome patients, potentially opening an entirely new therapeutic category for autoimmune diseases.
Biotechnology
Regeneron's Phase 3 NIMBLE trial data for cemdisiran demonstrates a paradigm shift in myasthenia gravis treatment. A quarterly subcutaneous injection achieves meaningful clinical outcomes with a favorable safety profile, potentially redefining patient care in this chronic neuromuscular disorder.
Policy
Trump's executive order fast-tracking FDA review of psychedelic drugs like psilocybin and ibogaine signals a major shift for mental health treatment and the biotech sector.
Biotechnology
Kailera Therapeutics' record-breaking $625 million IPO marks a pivotal moment in the obesity drug market, signaling investor confidence in Chinese-origin drug pipelines and validating a new model for biotech fundraising.
Biotechnology
Novartis CEO Vas Narasimhan's appointment to Anthropic's board marks a significant shift in pharmaceutical industry governance of AI technology, signaling that pharma is becoming a co-author of AI governance norms.
Biotechnology
Spyre Therapeutics' Phase 2 data for SPY001 demonstrates a credible challenge to Takeda's Entyvio blockbuster, with superior remission rates and the potential for quarterly or biannual dosing in ulcerative colitis treatment.
Biotechnology
Revolution Medicines' pan-RAS inhibitor daraxonrasib delivered a median overall survival of 13.2 months in metastatic pancreatic cancer—nearly doubling survival compared to standard chemotherapy. This Phase 3 breakthrough could reshape treatment paradigms for RAS-driven cancers.
Pharmaceuticals
The FDA faces its PDUFA deadline today on Travere Therapeutics' FILSPARI (sparsentan) for FSGS. If approved, it would be the first-ever therapy indicated for this rare, devastating kidney disease affecting 40,000 Americans.
Biotechnology
Gilead Sciences is acquiring German ADC biotech Tubulis for up to $5 billion, its third major oncology deal in 2026. The transaction reveals why antibody-drug conjugates have become the most fiercely contested technology platform in cancer drug development.
Biotechnology
Neurocrine Biosciences is paying $2.9 billion for Soleno Therapeutics and its first-in-class hyperphagia drug Vykat XR. The deal reveals how rare disease M&A works when the science finally catches up to a condition that has been waiting decades for a targeted therapy.
Biotechnology
Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals signals a strategic shift from neuroscience to immunology and rare disease, revealing new patterns in biotech M&A and corporate reinvention.